The Impact of Mindfulness-Based Stress Reduction on Emotional Wellbeing and Glycemic Control of Patients with Type 2 Diabetes Mellitus.

Author: Armani Kian A1, Vahdani B1, Noorbala AA2, Nejatisafa A2, Arbabi M2, Zenoozian S3, Nakhjavani M4
Affiliation: <sup>1</sup>Department of Psychiatry, Beheshti Hospital and Zanjan University of Medical Sciences, Zanjan 45136-15788, Iran. <sup>2</sup>Department of Psychiatry, Psychosomatic Medicine Research Center, Tehran University of Medical Sciences, Tehran, Iran. <sup>3</sup>Department of Clinical Psychology, Beheshti Hospital and Zanjan University of Medical Sciences, Zanjan, Iran. <sup>4</sup>Department of Endocrinology, Metabolism Research Center, Tehran University of Medical Sciences, Tehran, Iran.
Conference/Journal: J Diabetes Res.
Date published: 2018 Jun 10
Other: Volume ID: 2018 , Pages: 1986820 , Special Notes: doi: 10.1155/2018/1986820. eCollection 2018. , Word Count: 173


Objective: The aim of the study was to determine the effect of mindfulness-based stress reduction (MBSR) intervention on emotion regulation and glycemic control of patients with type 2 diabetes.

Materials and Methods: Sixty patients with type 2 diabetes were recruited for this randomized controlled trial from an outpatient clinic at Imam Hospital in Iran. The intervention group participated in 8 sessions of MBSR, and the control group continued the treatment as usual. Fasting blood sugar and HbA1c were measured as two indices of glycemic control. Overall mental health, depression, and anxiety were measured using the General Health Questionnaire (GHQ-28), Hamilton Depression Rating Scale (HDRS), and Hamilton Anxiety Rating Scale (HARS), respectively. All the assessments were performed at baseline and after 8 weeks and 3 months as follow-up.

Results: In comparison with the control group, the MBSR intervention group showed a significant reduction on all outcome measures including FBS, HbA1C, HARS, and HDRS scores (p < 0/05).

Conclusion: MBSR had a remarkable improvement on emotional wellbeing and glycemic control of patients with type 2 diabetes.

PMID: 29984258 PMCID: PMC6015675 DOI: 10.1155/2018/1986820